Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype

Lorenzo Gerratana(University of Udine), Grazia Arpino(University of Naples Federico II), Federica Martorana(University of Catania), Santino Minichillo(Azienda USL di Bologna), Mario Giuliano(Regione Campania), Andrea Coinu, Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Debora Basile(University of Udine), Giuseppe Buono(Federico II University Hospital), Fabio Puglisi(University of Udine), Irene De Santo(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cancer Treatment Reviews
June 11, 2018
10.1016/j.ctrv.2018.06.005
Cited by 282

Related Papers

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545